Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by Fabian Lorenz on March 13th, 2024 | 06:30 CET

Bayer disappoints, BioNTech share gives hope, and Cardiol Therapeutics with upside potential!

  • Biotechnology
  • Pharma
  • heartdisease

Analysts were anticipating a more favourable outcome from Bayer's Capital Markets Day. While the spin-off of Aspirin and Co. was expected, and there was also more transparency in the legal disputes, the actual results differed significantly. In some cases, analysts' share price targets plummeted by nearly 50%. In contrast, analysts have renewed their "Buy" recommendation for Cardiol Therapeutics shares. The specialist in cardiovascular diseases is facing exciting weeks and the share could certainly still more than double. There is also movement at BioNTech. In addition to operating figures, there will soon be an update on the drug pipeline. The question remains whether the share can halt its downward trend.

Read

Commented by Armin Schulz on March 6th, 2024 | 07:00 CET

Cardiol Therapeutics is on the upswing - When will BioNTech and Evotec follow suit?

  • Biotechnology
  • Pharma

In the world of biotechnology, the stock market often resembles a rollercoaster ride where investors and companies need to be firmly strapped in. The volatility of biotech companies can include dizzying highs and lows driven by the research and development of new medical treatments and therapies. A single positive report of clinical trial results or regulatory approval of a breakthrough drug can send a company's share price soaring, sending investors and companies into euphoria overnight. This happened recently with Cardiol Therapeutics. When can Evotec and BioNTech announce a success?

Read

Commented by Fabian Lorenz on February 7th, 2024 | 07:30 CET

BASF shares on the upswing, BioNTech sees breakthrough in cancer, and Defence Therapeutics benefits from study

  • Biotechnology
  • chemicals
  • Cancer

Can BASF shareholders look forward to better times? One analyst is certainly hopeful. He believes that the chemical industry will recover in 2024. However, the price target gives pause for thought. The development of cervical cancer is also concerning. According to a new study, the number of cases has risen sharply in recent years, and with it, HPV infections. Accordingly, more HPV vaccines are urgently needed. The market volume is expected to more than double to over USD 15 billion in just a few years. Defence Therapeutics aims to become a profiteer. The biotech company is fighting cancer with its Accum™ platform. BioNTech CEO Ugur Sahin also believes that humanity will get cancer under control, thanks in part to artificial intelligence. The Company is currently working on 30 cancer therapies. Is it a good time to invest now?

Read

Commented by Armin Schulz on January 30th, 2024 | 06:30 CET

BioNTech, Cardiol Therapeutics, Evotec - Biotech upswing post-Corona

  • Biotechnology
  • Covid19
  • Biotech

After the hype caused by the Corona vaccines, many biotech companies experienced a lull. However, there are now increasing signs of a revival, and with good reason. After a period of stagnation caused by market saturation and investor reluctance, fresh scientific breakthroughs and innovative therapeutic approaches are attracting investors and driving the sector to new heights. German biotech companies have managed to raise more funds than in the previous year despite the challenging conditions in the financial markets. Today, we look at three interesting companies and highlight their opportunities for this year.

Read

Commented by André Will-Laudien on January 15th, 2024 | 06:45 CET

Biotech: Corona is back! The doublers are lurking here: BioNTech, Evotec, Defence Therapeutics and Bayer

  • Biotechnology
  • Pharma
  • Covid19

We had almost forgotten about Corona and the good old flu, but it is back in full swing. Governments are remaining calm and holding on to their regained liberalism. However, Spain is now resorting to drastic measures again to protect vulnerable population groups. A mask is to be compulsory again in all Spanish healthcare facilities due to the increase in respiratory diseases. Health Minister Mónica García had previously failed to convince the Spanish regions of the need to introduce compulsory masks of their own accord. In some parts of the country, hospital emergency rooms are under severe pressure due to high patient numbers. Biotech stocks are showing the first signs of recovery after the sell-off in 2023. We take a look at a few selected stocks with 100% potential.

Read

Commented by Juliane Zielonka on January 10th, 2024 | 12:00 CET

Cardiol Therapeutics, Morphosys, BioNTech - Who will switch to the fast lane in 2024?

  • Biotechnology
  • Cancer

The life science and biotech sector has a few aces up its sleeve in 2024. Cardiol Therapeutics announces a significant clinical milestone, with over 50% of participants now enrolled in the ARCHER trial for acute myocarditis. MorphoSys, a cancer drug company, is developing an oral therapy specifically for proteins against myelofibrosis with the promising compound "pelabresib". However, analysts disagree on the share valuation. Top dog BioNTech is planning sales of EUR 3 billion in 2024, also focusing on oncology. CEO Uğur Şahin emphasizes the strategic scaling of the cancer therapy business by 2025 and initial market launches by 2026. Who will use 2024 to move into the fast lane?

Read

Commented by André Will-Laudien on January 2nd, 2024 | 07:10 CET

Returns beckon here: The Biotech favorites for 2024! BioNTech, Pfizer, Cardiol Therapeutics and MorphoSys in focus

  • Biotechnology

The past year was a disaster for investors in the Biotech sector - no golden check as often seen before. Despite all the gloom, the key indicator, the Nasdaq Biotechnology Index (NBI), has managed an annual gain of around 7% since the end of October, thanks to a fabulous 15% upswing. The index was temporarily down 12%. High capital costs made it difficult for research-based companies to refinance, and it is only now, with falling inflation rates, that interest rate hopes are reviving. The 10-year yield in the US fell by more than 100 basis points from 4.98% to 3.84% in a short space of time. Now, the industry senses a positive outlook again. At the end of the year, the positive environment helped some Biotech stocks shake off the negative trend and initiate a turnaround. Which stocks should we focus on?

Read

Commented by Fabian Lorenz on December 28th, 2023 | 07:30 CET

Morphosys with 50% risk? BioNTech and Defence Therapeutics share with positive news

  • Biotechnology
  • Pharma

Will the Morphosys share price halve? Analysts believe this is possible, although the German biotech veteran has been one of the winners in the sector this year. Overall, biotech shares were not among the favorites of investors in 2023. Nevertheless, the billion-dollar takeover of Karuna Therapeutics by Bristol-Myers Squibb announced yesterday gives the sector hope for a better performance in 2024. Today, we are focusing on three companies of different sizes, including Morphosys and Defence Therapeutics. The biotech company with a focus on immuno-oncology is closing the year with further positive news. The FDA has given the green light for the start of trials next year, which could open up a market worth billions. BioNTech has several pieces of positive news. Here, too, the FDA has made a positive statement, and the Company has achieved a milestone victory against CureVac.

Read

Commented by Fabian Lorenz on December 13th, 2023 | 07:30 CET

Several 100% upside potential? BioNTech, Bayer, Cardiol Therapeutics and Evotec in analyst check

  • Biotechnology
  • Pharma

We take a look at analysts' opinions on biotech and pharmaceutical stocks. Jefferies recently renewed its "Buy" recommendation for Evotec with a target price of EUR 34. The latest partnerships confirm that the Company's unique business model is working. The situation at Bayer is quite different. While the CEO is announcing radical changes, analysts are slashing their price targets, in some cases significantly. In contrast, analysts believe that Cardiol Therapeutics could achieve several 100% gains. The cash register is full to bursting, and an exciting news flow can be expected in 2024. At BioNTech, only the cash position is currently convincing. However, this is not enough for a buy recommendation.

Read

Commented by André Will-Laudien on December 12th, 2023 | 13:40 CET

Game Changer in Cancer - The Biotech Gold List for 2024! MorphoSys, Defence Therapeutics, BioNTech and Bayer

  • Biotechnology
  • Pharma
  • Cancer

The International Agency for Research on Cancer estimates the number of cancer deaths worldwide for the year 2022 to be around 10 million. However, the number of new cancer cases in the same year amounted to around 20 million, and cancer is still considered incurable. Lung cancer remains the sad frontrunner, claiming the most lives worldwide. Colorectal and stomach cancer follow at a considerable distance. However, since the original launch of the "Cancer Moonshot" in 2016, the fight against this incurable disease in the US has made some progress in the realization of therapies. Recently, there has been an increase in success stories from many biotech companies, and investors' enthusiasm is palpable once again. Where are the Biotech game changers lurking for the 2024 investment year?

Read